Previous 10 | Next 10 |
home / stock / medxf / medxf news
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 6, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the closing of its bought-deal public offering of 3,389,900 units ( Units ) at a price of C$2.95 per Unit for aggregate gross proceeds to Medexus o...
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 28, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company recently entered into a third amendment to its February 2021 exclusive license agreement with medac GmbH relating to commercial...
All director nominees reelected and all other company proposals approved by shareholders Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 21, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders e...
2023-09-06 06:34:13 ET Medexus Pharmaceuticals ( OTCQX:MEDXF ) entered into an agreement with Research Capital as sole bookrunner and sole underwriter, pursuant to which the underwriter has agreed to purchase, on a bought-deal basis, 3.34M units at a price of C$2.95 per unit. Gr...
TORONTO and CHICAGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (" Medexus " or the " Company ") (TSX: MDP) (OTCQX: MEDXF) , is pleased to announce that it has entered into an agreement with Research Capital Corporation, as sole bookrunner and sole underwriter (th...
2023-09-05 12:49:49 ET More on Medexus Pharmaceuticals Inc. Medexus Pharmaceuticals Inc ( OTCQX:MEDXF ) Q1 2024 Earnings Call Transcript Medexus Pharmaceuticals Inc. ( OTCQX:MEDXF ) Q4 2023 Earnings Call Transcript For further details see: Medexus amends ...
Medexus expects net proceeds, together with projected cash on hand, to fully satisfy convertible debentures in cash at maturity in October 2023 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 5, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into an a...
Poster presentation at National Hemophilia Foundation (NHF) Bleeding Disorders Conference 2023 highlights effective prophylaxis, control of bleeding episodes, and consistent safety profile Phase 3/4 data presentation follows FDA acceptance for review of IXINITY® supplemental Biological Li...
2023-08-10 14:29:08 ET Medexus Pharmaceuticals Inc (MEDXF) Q1 2024 Earnings Conference Call August 10, 2023, 08:00 AM ET Company Participants Magda Gardner - IR Ken d'Entremont - CEO Marcel Konrad - CFO Conference Call Participants Andre Uddin - Resea...
Fiscal Q1 2024 revenue reflects a 37% increase over fiscal Q1 2023, demonstrating strong revenue growth and continued overall performance Management to host conference call at 8:00 AM Eastern time on Thursday, August 10, 2023 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 9...
News, Short Squeeze, Breakout and More Instantly...
Medexus Pharmaceuticals Inc Company Name:
MEDXF Stock Symbol:
OTCMKTS Market:
Medexus Pharmaceuticals Inc Website:
FDA has Accepted for Review the Treosulfan NDA Management to host conference call at 8:00 AM Eastern time on Wednesday, June 26, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and...
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June 26, 2024 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended Mar...
2024-06-06 12:08:44 ET In the United States, a new drug application, or NDA, is the vehicle through which drug sponsors formally propose that the FDA approve a new %Pharmaceutical for sale and marketing. And news that the FDA has accepted this firm’s resubmission is sending share...